GlycoMimetics (GLYC) Stock Price, News & Analysis

Company Overview

GlycoMimetics, Inc., a biotechnology company, focuses on the discovery and development of therapies for cancers and inflammatory diseases in the United States. It develops uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML), as well as completed phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and GMI-2093, a galectin-3 carbohydrate-binding protein. In addition, its portfolio comprises GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of osteosarcoma. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.

Key Stats

• Today's Range: $0.31 to $0.37
• 50-Day Range: $0.14 to $0.49
• 52-Week Range: $0.14 to $3.53
• Volume: 3.46 million shs
• Average Volume: 7.12 million shs
• Market Capitalization: $21.28 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $10.00
• Consensus Rating: Hold

GlycoMimetics Stock Analysis - MarketRank™

GlycoMimetics scored higher than 73% of companies evaluated by MarketBeat, and ranked 251st out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.0 / 5
• Analyst Rating: Hold

Consensus Rating

GlycoMimetics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.

Amount of Analyst Coverage

GlycoMimetics has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

GlycoMimetics has a P/B Ratio of 0.55. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

8.75% of the outstanding shares of GlycoMimetics have been sold short.

Short Interest Ratio / Days to Cover

GlycoMimetics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in GlycoMimetics has recently increased by 208.20%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

GlycoMimetics does not currently pay a dividend.

Dividend Growth

GlycoMimetics does not have a long track record of dividend growth.

Sustainability and ESG

• Score: 4.6 / 5
• Environmental Score: -0.55

Percentage of Shares Shorted

8.75% of the outstanding shares of GlycoMimetics have been sold short.

Short Interest Ratio / Days to Cover

GlycoMimetics has a short interest ratio ("days to cover") of 0.3, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in GlycoMimetics has recently increased by 208.20%, indicating that investor sentiment is decreasing significantly.

News and Social Media

• Score: 1.1 / 5
• News Sentiment: N/A

Search Interest

2 people have searched for GLYC on MarketBeat in the last 30 days.

MarketBeat Follows

3 people have added GlycoMimetics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, GlycoMimetics insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 8.70% of the stock of GlycoMimetics is held by insiders.

Percentage Held by Institutions

75.19% of the stock of GlycoMimetics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

GLYC Stock Analysis - Frequently Asked Questions

How have GLYC shares performed this year?

GlycoMimetics' stock was trading at $2.36 at the beginning of the year. Since then, GLYC stock has decreased by 86.0% and is now trading at $0.33.
View the best growth stocks for 2024 here.

How were GlycoMimetics' earnings last quarter?

GlycoMimetics, Inc. (NASDAQ:GLYC) issued its quarterly earnings data on Friday, November, 3rd. The biotechnology company reported ($0.14) earnings per share for the quarter, hitting analysts' consensus estimates of ($0.14).

Who are GlycoMimetics' major shareholders?

GlycoMimetics' top institutional shareholders include LMR Partners LLP. Insiders that own company stock include Public Equities LP Invus, Edwin Rock, Bruce S Johnson, Brian M Hahn and John L Magnani.
View institutional ownership trends.

How do I buy shares of GlycoMimetics?

Shares of GLYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

What other stocks do shareholders of GlycoMimetics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that GlycoMimetics investors own include NVIDIA (NVDA), Viking Therapeutics (VKTX), Palantir Technologies (PLTR), Bristol-Myers Squibb (BMY), Meta Platforms (META), Advanced Micro Devices (AMD) and Alibaba Group (BABA).

Company Calendar

• Last Earnings: 11/03/2023
• Today: 11/20/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:GLYC
• CUSIP: N/A
• CIK: 1253689
• Web: www.glycomimetics.com
• Phone: (240) 243-1201
• Fax: 301-738-2137
• Employees: 50
• Year Founded: N/A

Price Target and Rating

• Average Stock Price Target: $10.00
• High Stock Price Target: $12.00
• Low Stock Price Target: $8.00
• Potential Upside/Downside: +2,930.3%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-36,900,000.00
• Net Margins: N/A
• Pretax Margin: -397,340.00%
• Return on Equity: -160.93%
• Return on Assets: -132.85%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.62
• Quick Ratio: 3.62

Sales & Book Value

• Annual Sales: $10,000.00
• Price / Sales: 2,127.84
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.60 per share
• Price / Book: 0.55

Miscellaneous

• Outstanding Shares: 64,480,000
• Free Float: 58,874,000
• Market Cap: $21.28 million
• Optionable: Optionable
• Beta: 1.85